Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma

Published:2014-02-12 Issue:4 Volume:3 Page:232-236
ISSN:2192-3183
Container-title:International Cancer Conference Journal
language:en
Short-container-title:Int Canc Conf J

Author:

Shimada Hiedaki,Nagata Matsuo,Nabeya Yoshihiro,Yajima Satoshi,Oshima Yoko,Itami Makiko

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s13691-014-0153-y.pdf

Reference13 articles.

1. Shimada H, Ochiai T (2007) Molecular diagnosis and treatment for esophageal carcinoma with p53. Esophagus 4:165–168

2. Kato H, Nakajima M, Fukuchi M (2005) Serum p53 antibodies in drainage blood from the azygos vein in patients with esophageal carcinoma. Anticancer Res 25:3231–3235

3. Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683

4. Shimada H, Nagata M, Cho A et al (2013) Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. doi: 10.1007/s00595-013-0787-y

5. Shimada H, Nabeya Y, Okazumi S et al (2000) Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132:41–47

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of serum galectin‑1 autoantibodies in seven types of cancer: A potential biomarker;Molecular and Clinical Oncology;2021-07-01